(News Bulletin 247) – Oddo BHF maintains its Outperformance rating on the Novo Nordisk share, with a target price of 1,210 Danish kroner.

The announcement by Novo of the results of the Oasais program aimed at evaluating semaglutide is welcomed by the analyst: ‘This trial is a success and confirms Novo’s leadership in the indication’.

These results therefore reinforce Novo Nordisk’s expertise as well as its field of action in the control of obesity. They should also ‘reassure investors in Novo Nordisk’s ability to respond both to demand but also to position itself as a pioneer in a substantial market’ continues the analyst.

Copyright (c) 2023 News Bulletin 247. All rights reserved.